What's new

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised

Feb 27, 2025 - 16:53
 0
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 17, Status: Authorised
Read More

Tags:

Previous Article

Peru leads the way in embracing STAR to make tourism a pillar of rural development

Next Article

New generation is a ‘better approach’ to energy security than transmission: ERCOT

Related Posts

Human medicines European public assessment report (EPAR): Zinforo, ceftaroline fosamil, Date of authorisation: 22/08/2012, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025  0

Agenda of the CAT meeting 19-21 February 2025

Feb 18, 2025  0

International Coalition of Medicines Regulatory Authorities (ICMRA)

International Coalition of Medicines Regulatory Authori...

Feb 17, 2025  0